Pharmacogenetic study of serotonin 6 receptor gene with antidepressant response in major depressive disorder in the Japanese population

✍ Scribed by Taro Kishi; Yasuhisa Fukuo; Reiji Yoshimura; Tomo Okochi; Tsuyoshi Kitajima; Hiroshi Naitoh; Wakako Umene-Nakano; Jun Nakamura; Norio Ozaki; Nakao Iwata

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 73 KB
• Volume: 25
• Category: Article
• ISSN: 0885-6222
• DOI: 10.1002/hup.1142

✦ Synopsis

Abstract

Objective

Several investigations have suggested that alterations in serotonin 6 (5‐HT6) receptors might be associated with the pathophysiology of major depressive disorder (MDD), and that 5‐HT6 receptors might be a therapeutic target for serotonin selective reuptake inhibitor (SSRI) in MDD. To evaluate the association between HTR6 and the efficacy of SSRI treatment in Japanese MDD patients, we conducted a case‐control study in a Japanese population sample.

Methods

We selected five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), and performed an association analysis of HTR6 and the efficacy of SSRI treatment in 260 MDD patients.

Results

We did not detect an association between tagging SNPs in HTR6 and the therapeutic response to SSRI in MDD in allele/genotype or haplotype analysis.

Conclusions

HTR6 may not play an important role in the pathophysiology of SSRI response in the Japanese population. Because our sample was relatively small, statistical errors were possible in the results of our association analyses. To overcome these limitations, a replication study using a larger sample may be required for conclusive results. Copyright © 2010 John Wiley & Sons, Ltd.